Background: Prescription drug misuse (PDM) rates are highest in adolescents and young adults. Little research in these high-risk groups has examined PDM differences by educational status or attainment. This investigation attempted to further our understanding of adolescent and young adult prescription drug use and misuse through examining PDM type (i.e., nonmedical misuse, medical misuse and mixed misuse) and substance use disorder (SUD) symptoms from PDM by educational status/attainment.
INTRODUCTION
Prescription drug misuse (PDM) has been described as an epidemic (e.g., Kanouse and Compton, 2015; McClure, 2015) , as rates of PDM-related overdose, emergency department and treatment utilization rise (DAWN, 2013; SAMHSA, 2014) . PDM may be especially problematic in adolescents (12-17 years) and young adults (18-25 years), as they consistently have elevated past-year PDM prevalence rates from the most commonly misused medication classes: opioids, stimulants, sedatives and tranquilizers (CBHSQ, 2016b) .
Lifetime (Havens et al., 2011; Rigg and Ford, 2014) and past-year (Martins et al., 2015; Schepis and Krishnan-Sarin, 2008) adolescent and young adult PDM is linked to concerning outcomes, including poorer academic performance, psychopathology, and risky behavior. Nonetheless, the PDM literature in these groups is limited by near exclusive use of schoolor college-based samples. When investigated by dichotomous school enrollment, past-year PDM prevalence rates differ in adolescents (Edlund et al., 2015) and young adults (Ford and Pomykacz, 2016; Johnston et al., 2016; Martins et al., 2015; SAMHSA, 2005; . Despite these findings, no research has followed to investigate whether more fine-grained educational differences affect PDM (e.g., level of educational attainment in young adults not in college).
Similarly, past-year PDM type and PDM-related substance use disorder (SUD) symptoms are under-investigated (McCabe et al., 2013; McCabe et al., 2012) . Type captures how the medication was misused and is one of: medical misuse (i.e., use in ways the prescriber did not intend), nonmedical misuse (i.e., use without a prescription) or mixed misuse (i.e., a combination of medical and nonmedical misuse). PDM type may affect use patterns (McCabe et al., 2013) and SUD symptoms highlight elevated PDM-related consequences (APA, 2013), suggesting both as important for further study.
While it appears that dichotomous school enrollment corresponds with PDM prevalence, the relationships between educational status/attainment and PDM type prevalence or PDMrelated SUD symptoms remain unclear. Also, PDM prevalence rates and prevalence of other PDM variables in more granular and under-studied subgroups (e.g., young adult college graduates or those with poor school adjustment [at-risk for HS dropout]) are relatively unknown. Clinically, data on PDM by education status/attainment can be valuable by providing workplace supervisors, clinicians and school professionals with an easily assessed characteristic suggesting more selective prevention and intervention by status/attainment (e.g., different medication classes of concern by group).
This investigation aimed to examine PDM, PDM-related types and SUD symptoms by educational status/attainment in adolescents and young adults, using 2015 National Survey on Drug Use and Health (NSDUH) data. We hypothesized that PDM and SUD symptom rates would be highest in adolescents not in school and young adults who did not complete high school (HS), given their higher substance use rates (DuPont et al., 2013; Grant et al., 2017) ; one exception should be stimulant-PDM, which was expected to be higher in college students (Ford and Pomykacz, 2016) . Given the limited PDM type data, we did not have a priori type hypotheses.
METHODS
The NSDUH produced nationally representative data via an independent, multistage area probability sample. Interviews began with audio computer-assisted self-interviewing (ACASI) for sensitive variables (e.g., PDM); ACASI promotes privacy, honest reporting and data completeness. The 2015 weighted interview response rate was 77.7% in adolescents and 74.5% in young adults; age-based weighted screening response rates (79.7% across ages) were not provided. For more on the NSDUH, see CBHSQ (2016a) and Hughes and colleagues (2016) .
Participants
For 2015, 13,585 adolescents (12-17 years) and 14,553 young adults (18-25 years) completed the NSDUH. In adolescents, the weighted sample was 51.0% male, 53.7% white, 13.9% African-American and 23.1% Hispanic/Latino; in young adults, the weighted sample was 50.2% male, 55.0% white, 14.4% African-American and 21.4% Hispanic/Latino. Online-only Supplemental Tables A and B capture demographic characteristics by educational status/attainment.
Measures
PDM variables were assessed separately by medication class (i.e., opioids, stimulants and sedative/tranquilizers), with sedative/tranquilizers aggregated, per previous studies (Schepis and Hakes, 2013; Tetrault et al., 2008) . To aid recall, individual drug names were used, and pictures of common medications were provided. In lifetime users of medication class, pastyear prescription use was assessed. Then, past-year PDM was assessed: "The next question asks about using [drug class] in any way a doctor did not direct you to use them. [P]lease think only about your use of the drug in any way a doctor did not direct you to use it, including: Using it without a prescription of your own; Using it in greater amounts, more often, or longer than you were told to take it; Using it in any other way a doctor did not direct you to use it."
In past-year misusers, PDM type was assessed with: "Which of these statements describe your use of [drug class] at any time in the past 12 months?" Use without a prescription from a prescriber is nonmedical misuse; these four subtypes are medical misuse: (1) in greater amounts, (2) over a longer period, (3) more often, or (4) in some other way the prescriber did not intend. Participants selected as many of the statements as applied, and the combination of nonmedical misuse and medical misuse is mixed misuse. Finally, in pastyear misusers, DSM-IV SUD symptoms (APA, 2000) were assessed. The 10 DSM-5 (APA, 2013) symptoms were retained, and participants were categorized as having zero, one or two or more SUD symptoms from each medication class. SUD symptom categories were chosen to highlight initial impairment or distress from symptomatic PDM (one symptom; Compton et al., 2013) or symptoms consistent with the DSM-5 SUD diagnosis (≥ two symptoms; APA, 2013), given the relative equality of SUD symptoms found elsewhere (Dawson et al., 2010; Hasin et al., 2013) .
Participants were categorized by educational status/attainment. In adolescents, participants were home-schooled; in school, good school adjustment; in school, poor school adjustment; not in school. Poor school adjustment was based on school dropout risk factors (Hammond et al., 2007) and was positive with at least one of: (1) D or worse grades in the last grading period; (2) history of being retained in grade; and/or (3) stating that the respondent "hated going to school". In young adults, participants were still in HS; full-time in college; parttime in college; college graduate; not in college, HS graduate; not in college, less than HS. College status comprised those enrolled in "college or university" and included 2-and 4year schools and post-baccalaureate schooling.
Analyses
Data were weighted, clustered on primary sampling units, and stratified appropriately. The Taylor series approximation was used, with adjusted degrees of freedom, to create robust variance estimates. Analyses occurred separately by medication class. Initial analyses employed weighted cross-tabulations to estimate prevalence and 95% confidence intervals of past-year medication use and all PDM variables by educational status/attainment. Primary analyses used design-based logistic (PDM prevalence) and multinomial regression (PDM type and SUD symptoms) to examine PDM variable differences by educational status/ attainment, controlling for age, race/ethnicity and sex; post hoc pairwise comparisons used the same covariates, with Bonferroni-corrected p-values. Analyses were performed in Stata 15.0 (StataCorp, 2017).
RESULTS

Use, PDM, PDM-Related Types and SUD Symptoms in Adolescents
For opioids, adolescents not in school had both the highest use and PDM rates, while stimulant and sedative/tranquilizer use and PDM rates were higher in adolescents with poor school adjustment. For PDM-related SUD symptoms, adolescents with poor school adjustment had the highest prevalence of symptomatic PDM (or the lowest prevalence of zero SUD symptoms). The lowest prevalence rates for PDM outcomes were in adolescents with good school adjustment or homeschooled adolescents, who were not included in the statistical tests due to their small sample. PDM type differences were limited, with nonmedical misuse as the most prevalent type. For adolescent outcomes, please see Table 1 .
Use, PDM, PDM-Related Types and SUD Symptoms in Young Adults
In contrast to adolescents, PDM variable patterns differed by medication class between educational subgroups in young adults, with the starkest differences between opioids and stimulants. For opioids, rates of any use, PDM, PDM type and SUD symptoms were significantly higher in those not in college than in college graduates or full-time college students. The pattern reversed for stimulant-PDM, with the highest prevalence rates of PDM 
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Author Manuscript and SUD symptoms in full-time college students and graduates. Outcomes mirrored the opioid-PDM pattern for sedatives/tranquilizers: higher rates in young adults not in school, with fewer significant differences. Young adults in HS had lower sedative/tranquilizer-PDM rates than all subgroups except college graduates. Nonmedical misuse was again the most prevalent type. For young adult outcomes, please see Table 2 .
DISCUSSION
This work highlights adolescents not in school or with poor school adjustment as having elevated rates of PDM, nonmedical misuse and SUD symptoms. Those with poor school adjustment were similar to those not in school, suggesting that PDM elevations predate HS dropout (DuPont et al., 2013) . Identifying adolescents in school engaged in PDM may limit both direct and indirect PDM consequences, which could include HS dropout. Outreach to adolescents not in school requires community-based efforts (National Research Council, 1993) , including parental education about medication storage and disposal, as family is a key source for PDM (Schepis and Krishnan-Sarin, 2009 ). Finally, while not formally tested, homeschooled adolescents had generally low rates of PDM and associated variables, suggesting them as a focus for investigations of protective factors against PDM.
In young adults, those not in school had the highest opioid-PDM and SUD rates, as found previously (Johnston et al., 2016; Martins et al., 2015) . Conversely, full-time students and college graduates had higher stimulant-PDM and stimulant SUD symptom rates. While young adults with higher levels of educational attainment have lower substance use rates (e.g., Grant et al., 2017) , the elevated stimulant-PDM in full-time college students here and in Ford and Pomykacz (2016) may result from the predominant studying-related motives (Teter et al., 2006) and perceived academic benefits of stimulant-PDM (Arria et al., 2018) . In these subgroups, elevated stimulant-PDM mirrored elevated rates of any stimulant use, with this positive relationship between any use and PDM seen broadly across subgroups and medication classes. Clinically, these findings may highlight screening and intervention for opioid-PDM in medical or workplace settings, given the challenges of reaching young adults not in school, versus those in college. These findings also underline the value of intervening to reduce college student stimulant-PDM, as elevated rates persist post-graduation; finally, they raise the question of when, or if, these rates decline post-graduation.
The PDM profiles of adolescents with poor school adjustment and young adults not in school were similar, while adolescents with good school adjustment did not evidence the elevated stimulant-PDM rates of young adults continuing in education. Thus, primary school-based intervention to alter the developmental trajectory of adolescents who are likely to have poor school adjustment and intervention in first-year college students to limit stimulant-PDM would have value.
For PDM type, the non-significant but higher opioid nonmedical misuse rates in adolescents with poor school adjustment or not in school may be reason for concern. Schepis and Krishnan-Sarin (2009) found that adolescent nonmedical misusers had higher rates of other substance use and frequent PDM than medical misusers. Adolescent nonmedical opioid and stimulant misusers also have higher rates of SUD symptoms in adulthood (McCabe et al., Schepis et 
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Author Manuscript 2017; McCabe et al., 2016) . However, medical misuse is associated with poorer outcomes than nonmedical misuse, depending on underlying motives (McCabe et al., 2013) , and even medical use can impart risk, as adolescent opioid users have higher follow-up opioid-PDM rates than non-users (McCabe et al., 2016; Miech et al., 2015) .
Three limitations should be noted: (1) cross-sectional data, preventing causal inference; (2) self-selection bias, given participation refusal; and, (3) self-report bias. Despite these limitations, this investigation highlighted adolescents with poor school adjustment as more likely to engage in PDM and have PDM-related SUD symptoms, found elevations in stimulant-PDM post-college graduation, and noted young adults not in college as highest risk for opioid-PDM. These data can aid school health professionals and clinicians by emphasizing adolescents not in school or with poor school adjustment for prevention and more careful prescribing and monitoring. College-based interventions in first-year students aimed at stimulant-PDM and workplace prevention for opioid-PDM in young adults are also warranted.
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